Home

Commentary

直肠癌治疗方法日趋复杂
The Increasingly Complicated Approach to Rectal Cancer
David P. Ryan
The Oncologist 2019; 24:728-729; first published on April 17, 2019; doi:10.1634/theoncologist.2018-0355





Clinical Trial Results

关于脱氢表雄酮治疗雄激素受体-阳性转移性乳腺癌的 II 期研究
Phase II Study of Dehydroepiandrosterone in Androgen Receptor‐Positive Metastatic Breast Cancer
Elisabetta Pietri, Ilaria Massa, Sara Bravaccini, Sara Ravaioli, Maria Maddalena Tumedei, Elisabetta Petracci, Caterina Donati, Alessio Schirone, Federico Piacentini, Lorenzo Gianni, Mario Nicolini, Enrico Campadelli, Alessandra Gennari, Alessandro Saba, Beatrice Campi, Linda Valmorri, Daniele Andreis, Francesco Fabbri, Dino Amadori, Andrea Rocca
The Oncologist 2019; 24:743-e205; first published on December 27, 2018; doi:10.1634/theoncologist.2018-0243

索拉非尼加用长春氟宁治疗经铂类药物治疗后转移性尿路上皮癌的安全性和活性(温莎):I 期试验
Safety and Activity of Sorafenib in Addition to Vinflunine in Post‐Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial
Carl‐Henrik Shah, Helle Pappot, Mads Agerbæk, Karin Holmsten, Fredrik Jäderling, Jeffrey Yachnin, Per Grybäck, Hans von der Maase, Anders Ullén
The Oncologist 2019; 24:745-e213; first published on December 14, 2018; doi:10.1634/theoncologist.2018-0795

采用 II 期扩展队列的开放标签、多中心、I 期剂量递增研究旨在确定静脉注射 TKM-080301 在晚期肝细胞癌受试者中的安全性、药代动力学和初步抗肿瘤活性
An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma
Imane El Dika, Ho Yeong Lim, Wei Peng Yong, Chia‐Chi Lin, Jung‐Hwan Yoon, Manuel Modiano, Bradley Freilich, Hye Jin Choi, Tsu‐Yi Chao, Robin K. Kelley, Joanne Brown, Jennifer Knox, Baek‐Yeol Ryoo, Thomas Yau, Ghassan K. Abou‐Alfa
The Oncologist 2019; 24:747-e218; first published on December 31, 2018; doi:10.1634/theoncologist.2018-0838

SOXIRI(S-1/奥沙利铂/伊立替康)三联化疗治疗无法切除的胰腺导管腺癌患者的 II 期研究
Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma
Takahiro Akahori, Masayuki Sho, Hiroaki Yanagimoto, Sohei Satoi, Minako Nagai, Satoshi Nishiwada, Kenji Nakagawa, Kota Nakamura, Tomohisa Yamamoto, Satoshi Hirooka, So Yamaki, Naoya Ikeda
The Oncologist 2019; 24:749-e224; first published on January 24, 2019; doi:10.1634/theoncologist.2018-0900

胶束化紫杉醇联合顺铂诱导局部晚期头颈部鳞癌化疗的 II 期研究
A Phase II Study of Genexol‐PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Bhumsuk Keam, Keun‐Wook Lee, Se‐Hoon Lee, Jin‐Soo Kim, Jin Ho Kim, Hong‐Gyun Wu, Keun‐Yong Eom, Suzy Kim, Soon‐Hyun Ahn, Eun‐Jae Chung, Seong Keun Kwon, Woo‐Jin Jeong, Young Ho Jung, Ji‐Won Kim, Dae Seog Heo
The Oncologist 2019; 24:751-e231; first published on February 22, 2019; doi:10.1634/theoncologist.2019-0070


Breast Cancer

在三阴性乳腺癌患者的新辅助化疗中检测血清 VEGF:关于早期预测患者治疗反应和生存期的全新策略
Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple‐Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival
Ruo‐Xi Wang, Sheng Chen, Liang Huang, Ying Zhou, Zhi‐Ming Shao
The Oncologist 2019; 24:753-761; first published on August 20, 2018; doi:10.1634/theoncologist.2017-0602

在当前早期乳腺癌的临床实践中,在化疗方案治疗期间患者报告的毒性
Patient‐Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer
Kirsten A. Nyrop, Allison M. Deal, Shlomit S. Shachar, Ethan Basch, Bryce B. Reeve, Seul Ki Choi, Jordan T. Lee, William A. Wood, Carey K. Anders, Lisa A. Carey, Elizabeth C. Dees, Trevor A. Jolly, Katherine E. Reeder‐Hayes, Gretchen G. Kimmick, Meghan S. Karuturi, Raquel E. Reinbolt, JoEllen C. Speca, Hyman B. Muss
The Oncologist 2019; 24:762-771; first published on December 14, 2018; doi:10.1634/theoncologist.2018-0590

甲磺酸艾瑞布林作为局部复发或转移性乳腺癌老年患者的三线或后线化疗:GIOGer(意大利老年肿瘤研究小组)-ERIBE 的多中心观察研究
Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)‐ERIBE
Silvana Leo, Ermenegildo Arnoldi, Lazzaro Repetto, Zaira Coccorullo, Saverio Cinieri, Palma Fedele, Marina Cazzaniga, Vito Lorusso, Agnese Latorre, Giovanna Campanella, Mariangela Ciccarese, Caterina Accettura, Salvatore Pisconti, Antonio Rinaldi, Cosimo Brunetti, Mimma Raffaele, Luigi Coltelli, Salvatore Spazzapan, Lucia Fratino, Luciana Petrucelli, Laura Biganzoli
The Oncologist 2019; 24:e232-e240; first published on November 9, 2018; doi:10.1634/theoncologist.2017-0676


European Perspectives

对在既往曾接受治疗的晚期非小细胞肺癌患者中对比厄洛替尼和安慰剂与厄洛替尼和 Tivantinib (MARQUEE) 的 III 期研究中的血清蛋白质组学检测的回顾性评估
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non‐Small Cell Lung Cancer
Consuelo Buttigliero, Frances A. Shepherd, Fabrice Barlesi, Brian Schwartz, Sergey Orlov, Adolfo G. Favaretto, Armando Santoro, Vera Hirsh, Rodryg Ramlau, Adele R. Blackler, Joanna Roder, David Spigel, Silvia Novello, Wallace Akerley, Giorgio V. Scagliotti
The Oncologist 2019; 24:e251-e259; first published on August 23, 2018; doi:10.1634/theoncologist.2018-0089


Gastrointestinal Cancer

辅助化疗似乎对术前放疗和接受基于人群的倾向评分分析手术后的 ypTis-2N0 期直肠癌患者没有生存益处
Adjuvant Chemotherapy Seemed Not to Have Survival Benefit in Rectal Cancer Patients with ypTis‐2N0 After Preoperative Radiotherapy and Surgery from a Population‐Based Propensity Score Analysis
Xiang Hu, Ya‐Qi Li, Qing‐Guo Li, Yan‐Lei Ma, Jun‐Jie Peng, San‐Jun Cai
The Oncologist 2019; 24:803-811; first published on April 19, 2018; doi:10.1634/theoncologist.2017-0600

中国和美国胃癌年轻幸存者的预后:基于条件生存率确定长期结果
Prognosis of Young Survivors of Gastric Cancer in China and the U.S.: Determining Long‐Term Outcomes Based on Conditional Survival
Qi‐Yue Chen, Qing Zhong, Wei Wang, Shi Chen, Ping Li, Jian‐Wei Xie, Jia‐Bing Wang, Jian‐Xian Lin, Jun Lu, Long‐Long Cao, Mi Lin, Ru‐Hong Tu, Ze‐Ning Huang, Ju‐Li Lin, Hua‐Long Zheng, Zhi‐Yu Liu, Chao‐Hui Zheng, Jun‐Sheng Peng, Zhi‐Wei Zhou, Chang‐Ming Huang
The Oncologist 2019; 24:e260-e274; first published on November 23, 2018; doi:10.1634/theoncologist.2018-0220

高 IDO1 表达与根治性放化疗治疗肛门癌的患者的不良预后相关
High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy
Devarati Mitra, Nora K. Horick, Diane G. Brackett, Kent W. Mouw, Jason L. Hornick, Soldano Ferrone, Theodore S. Hong, Harvey Mamon, Jeffrey W. Clark, Aparna R. Parikh, Jill N. Allen, David P. Ryan, David T. Ting, Vikram Deshpande, Jennifer Y. Wo
The Oncologist 2019; 24:e275-e283; first published on February 12, 2019; doi:10.1634/theoncologist.2018-0794


Global Health and Cancer

针对中国癌症患者的 IBM 沃森肿瘤和临床实践之间的一致性研究
Concordance Study Between IBM Watson for Oncology and Clinical Practice for Patients with Cancer in China
Na Zhou, Chuan‐Tao Zhang, Hong‐Ying Lv, Chen‐Xing Hao, Tian‐Jun Li, Jing‐Juan Zhu, Hua Zhu, Man Jiang, Ke‐Wei Liu, He‐Lei Hou, Dong Liu, Ai‐Qin Li, Guo‐Qing Zhang, Zi‐Bin Tian, Xiao‐Chun Zhang
The Oncologist 2019; 24:812-819; first published on September 4, 2018; doi:10.1634/theoncologist.2018-0255


Gynecologic Oncology

接受卡铂化疗的卵巢癌患者的低镁血症和生存期
Hypomagnesemia and Survival in Patients with Ovarian Cancer Who Received Chemotherapy with Carboplatin
Wenli Liu, Aiham Qdaisat, Pamela T. Soliman, Lois Ramondetta, Gabriel Lopez, Santhosshi Narayanan, Shouhao Zhou, Lorenzo Cohen, Eduardo Bruera, Sai‐Ching J. Yeung
The Oncologist 2019; 24:e312-e317; first published on April 2, 2019; doi:10.1634/theoncologist.2018-0465


Health Outcomes and Economics of Cancer Care

从诊疗途径到真实世界数据:关于 EGFR 阳性非小细胞肺癌前期治疗的多中心前瞻性研究(MOST 研究)
From Diagnostic‐Therapeutic Pathways to Real‐World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR‐Positive Non‐Small Cell Lung Cancer (MOST Study)
Giulia Pasello, Giovanni Vicario, Fable Zustovich, Francesco Oniga, Stefania Gori, Francesco Rosetti, Andrea Bonetti, Adolfo Favaretto, Silvia Toso, Roberta Redelotti, Antonio Santo, Daniele Bernardi, Petros Giovanis, Cristina Oliani, Lorenzo Calvetti, Carlo Gatti, Giovanni Palazzolo, Zora Baretta, Alberto Bortolami, Laura Bonanno, Marco Basso, Jessica Menis, Donatella Da Corte, Stefano Frega, Valentina Guarneri, PierFranco Conte, on behalf of Veneto Oncology Network
The Oncologist 2019; 24:e318-e326; first published on March 7, 2019; doi:10.1634/theoncologist.2018-0712


Lung Cancer

奥希替尼用于治疗伴有脑转移的 EGFR 突变肺癌:单中心回顾性研究结果
Osimertinib for EGFR‐Mutant Lung Cancer with Brain Metastases: Results from a Single‐Center Retrospective Study
Lijia Xie, Seema Nagpal, Heather A. Wakelee, Gordon Li, Scott G. Soltys, Joel W. Neal
The Oncologist 2019; 24:836-843; first published on August 20, 2018; doi:10.1634/theoncologist.2018-0264


Brief Communications

紫杉烷类疗法用于小肠腺癌的回顾性分析
Retrospective Analysis of Taxane‐Based Therapy in Small Bowel Adenocarcinoma
Jeffrey D. Aldrich, Kanwal Pratap Singh Raghav, Gauri R. Varadhachary, Robert A. Wolff, Michael J. Overman
The Oncologist 2019; 24:e384-e386; first published on December 31, 2018; doi:10.1634/theoncologist.2018-0573